-
Mashup Score: 5
In a joint conference event on Monday, cell therapy pioneer Carl June revealed unpublished results showing that in around 1,500 patients treated with CAR-T therapies, no cases of secondary malignancy could be definitively linked to the treatment.
Source: www.biospace.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 1
Pfizer will go toe-to-toe with CSL Behring following the FDA’s Friday approval of its hemophilia B gene therapy Beqvez and will launch a warranty program based on the durability of response.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 135 Mid-Stage ALS Drugs to Watch - 22 day(s) ago
As the Phase III amyotrophic lateral sclerosis pipeline thins out, the ALS community is placing its hopes on earlier-stage trials sponsored by Denali Therapeutics, PTC Therapeutics and more.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 2
Affinia Therapeutics announced that new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system such as amyotrophic lateral sclerosis, as well as the Company’s high-yield manufacturing process, will be presented in several oral and poster sessions at the American Society of Gene and Cell Therapy 2024 Annual Meeting, being held May 7-11, 2024 in Baltimore, MD and virtually.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 4Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development - 1 month(s) ago
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 7AACR 2024: What Cancer Researchers Are Talking About - 1 month(s) ago
The American Association for Cancer Research (AACR)’s annual conference runs April 5 through April 10. BioSpace will have all the key data and news out of San Diego.
Source: www.biospace.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
After BrainStorm Cell Therapeutics withdrew its BLA in October 2023 for NurOwn, the company announced Tuesday that the FDA has agreed to the design of a Phase IIIb trial for its amyotrophic lateral sclerosis candidate under a Special Protocol Assessment.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 1BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS - 1 month(s) ago
BrainStorm Cell Therapeutics Inc. announced that it received written agreement from the U.S. Food and Drug Administration, under a Special Protocol Assessment, on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 25
Following disappointing Phase III results in less aggressive non-small cell lung cancer, AstraZeneca on Friday announced that Imfinzi improved progression-free and overall survival in patients with limited-stage small cell lung cancer.
Source: www.biospace.comCategories: General Medicine News, Oncologists1Tweet
Stanford and U Penn researchers found no link between #CARTcells therapies and the development of secondary T-cell malignancies. https://t.co/dEN3YOnxGj @parkerici #CellTherapy